ABBV Price Prediction Next Week
Analysis and Insights
Fundamental Analysis:
ABBVIE INC (ABBV) has shown strong growth potential with a 77% rating using the P/B Growth Investor model by Partha Mohanram, indicating sustained future growth in the Biotechnology & Drugs industry.
Technical Analysis:
- RSI: 40.37 (RSI 6), 56.21 (RSI 12), 58.34 (RSI 14) - Not overbought or oversold.
- MACD: Positive at 4.82, indicating bullish momentum.
- Stochastic Oscillator: K at 44.59, D at 56.44, suggesting a bearish crossover but not critical.
- Price Action: Closed at 210.01, high of 212.88, low of 208.74.
- Fibonacci Levels: Pivot at 213.25, resistance at 217.22 and 219.67, support at 209.29 and 206.84.
News Impact:
ABBV is involved in a trade secret case against Genmab, which may cause short-term volatility but isn't expected to severely impact the stock's upward trend.
Conclusion:
Based on the bullish technical indicators and strong fundamental analysis, ABBV is predicted to rise to approximately 215 next week. The buy recommendation is supported by the stock's growth potential and manageable risks.
Prediction: The stock price of ABBV is expected to rise to 215 next week. Buy.
ABBV Similar Chart Price Prediction
The price of ABBV is predicted to go up 12.39%, based on the high correlation periods with EQH. The similarity of these two price pattern on the periods is 96.87%.
ABBV
EQH
Up: 12.39%Similarity: 96.87%
ABBV Stock Forecast & Prediction For Years 2025, 2026, 2027, 2028, 2029 and 2030
Year
ABBV Price Forecast($)
Potential Return(%)
2025
181.340
0.070
2026
250.000
19.600
2027
250.000
19.600
2028
625.000
199.000
2029
310.000
48.300
2030
300.000
43.520
What is ABBV stock price prediction 2025 ?
What is ABBV stock price prediction 2026 ?
What is ABBV stock price prediction 2027 ?
What is ABBV stock price prediction 2028 ?
What is ABBV stock price prediction 2029 ?
What is ABBV stock price prediction 2030 ?
ABBV Revenue Forecast
ABBV EPS Forecast
ABBV FAQs
What is ABBV revenue forecast for next quarter？
What is ABBV eps forecast for next quarter？
ABBV VS S&P500
AbbVie supports a strong dividend yield, which should act as valuation support, as the cash flows to support the dividend look secure over the next several years.
AbbVie's strong entrenchment in the aesthetics business (gained through the Allergan acquisition) sets up very long product cycles for several key assets like Botox based on strong brand power and physician entrenchment.
AbbVie's next generation immunology drugs targeting the IL23 and JAK pathways should help mitigate the competitive threats facing Humira over the next five years.
ABBV Analyst's Forecast
Mohit Bansal
Wells Fargo
Buy
2025-02-03
Price Target
$195 → $210
Upside
+9.99%
Wells Fargo analyst Mohit Bansal downgraded Vertex Pharmaceuticals (VRTX) to Equal Weight from Overweight with an unchanged price target of $460. The firm sees limited upside for the shares in the near-term. Vertex lacks major catalysts this year and Wells does not believe the Alyftrek and suzetrigine launches are "needle movers" for the stock, the analyst tells investors in a research note. The firm favors shares of Gilead (GILD), AbbVie (ABBV), and Eli Lilly (LLY) to Vertex. Wells thinks Vertex may need to do more pipeline deals.
Gary Nachman
Raymond James
Buy
2025-02-03
Price Target
$218 → $220
Upside
+15.23%
Srikripa Devarakonda
Truist Securities
Strong Buy
2025-01-08
Price Target
$215 → $211
Upside
+18.66%
